
Time to Invest in L...


| Price and Volume | |
|---|---|
| Recent Price | 5.16 |
| 52 Week High | 5.58 |
| 52 Week Low | 2.68 |
| Avg. Daily Vol. (Mil) | 0.69 |
| Beta (3 year) | 1.77 |
| Share Related Items | |
| Mkt Cap (Mil) | 359.73 |
| Shares Out (Mil) | 69.72 |
| Float (Mil) | 68.65 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 2.70 |
| Current Ratio | 3.20 |
| LT Debt/ Equity | 0.04 |
| Total Debt / Equity | 0.11 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 9.53 |
| Price/Book | 5.92 |
| Price/Cash Flow | -21.60 |
| Per Share Data | |
| Earnings | -0.42 |
| Sales | 0.54 |
| Book Value | 0.87 |
| Cash Flow | -0.24 |
| Business Summary | |
|---|---|
| Cerus Corporation is a biomedical products company, which focuses on commercializing the INTERCEPT Blood System to enhance blood safety. | |
| General Information | |
| 2550 Stanwell Drive
Concord, CA 94520 |
|
| www.cerus.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 85 | |
| CEO: William M. Greenman | |
| Short Interest | |
| Current Month (Mil) | 7.06 |
| Previous Month (Mil) | 7.45 |
| Short Interest Ratio (Days) | 10.40 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -18.80 |
| Return on Investments | -27.00 |
| Profitability | |
| Gross Margin | 47.80 |
| EBIT Margin | -43.70 |
| Profit Margin | -45.90 |